Key result
Targeting host RNA-binding proteins shows broad-spectrum antiviral promise but faces ongoing clinical toxicity challenges.
Why the study?
Targeting host RNA-binding proteins could provide broad-spectrum antiviral activity with lower resistance risk, but translation requires balancing antiviral effects with preserving essential host functions.
Host RNA-binding proteins represent a viable target for broad-spectrum antiviral therapies, potentially offering a higher barrier to viral resistance compared to direct-acting antivirals.
Supports host RBP-targeted antivirals for broad-spectrum use; leaves open toxicity mitigation before clinical translation.
RNA-binding proteins (RBPs) regulate key host processes and facilitate viral replication. Certain antiviral RBPs limit infection and trigger immune responses. Targeting these proteins could yield broad-spectrum antiviral activity with a lower risk of resistance. Nonetheless, translating this approach into clinical use requires balancing antiviral activity with the preservation of essential host functions. This review explores current RBP-directed antivirals and considers key challenges and future research directions.
No takes yet. Share an insight, caveat, or question.
Sagnik Biswas (2026) conducted a review in Viral infections. Host RNA-binding protein (RBP) targeted antivirals was evaluated. Targeting host RNA-binding proteins offers a promising strategy for broad-spectrum antiviral therapies with a high barrier to viral resistance, though host toxicity remains a clinical challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: